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Current guidelines recommend treatment optimization in virologically suppressed patients through switching/
simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflamma-
tion/coagulation profiles may support therapeutic decisions. We undertook a prospective, non-randomized study 
to evaluate the efficacy and safety of switching to ABC/3TC from ZDV/3TC or TDF/FTC backbones, in 40 HIV-1 
infected patients with HIV-RNA levels <37 copies/mL (>24 months). Main endpoints were viral load levels, CD4+ T 
cells and toxicities after 48 weeks. Serum inflammation/coagulation markers (ESR, CRP, D-dimer and fibrinogen) 
and pro-inflammatory cytokines (IL-6, TNF-α, adiponectin, resistin) were evaluated. Baseline characteristics were 
similar in the two arms, with significantly lower values of e-GFR in patients on TDF/FTC. Markers of inflamma-
tion/coagulation and cytokine profile were also similar, except for higher values of resistin in patients on TDF/
FTC. During follow up, CD4+ T cells increased and viral load remained undetectable in both groups. Patient from 
ZDV/3TC had significantly greater changes in total cholesterol and serum creatinine. Markers of inflammation/
coagulation remained unchanged. Adiponectin significantly increased in patients from ZDV/3TC.
Switching to ABC/3TC was effective and safe. Inflammatory markers remained low in both groups. Some changes 
in metabolic, kidney and cytokine profiles were apparently specific for baseline cART treatment. 
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INTrODuCTION
The availability of several combination antiret-
roviral regimens (cART) has made possible a 
prolonged disease-free survival in the major-
ity of Human Immunodeficiency Virus type-1 
(HIV-1) infected individuals (Hogg et al., 1998; 
Mocroft et al., 2003). However, long-term treat-
ment with cART is often complicated by the 
development of antiretroviral resistance and 
drug-related toxicities, mainly represented by 
metabolic abnormalities, impairment of bone 
and renal function, and cardiovascular disease 
(CVD). Among nucleos(t)ide reverse transcrip-
tase inhibitors [N(t)RTIs], fixed dose combi-
nations of tenofovir-difumarate/emtricitabine 
(TDF/FTC) and abacavir/lamivudine (ABC/3TC) 
are widely used, due to their high antiviral po-
tency, good tolerability, and low risk of side ef-
fects (DeJesus et al., 2004; Gallant et al., 2006). 
These backbones have been extensively evalu-
ated in controlled trials (Eron et al., 2006; Al-
brecht, 2008; Sax et al., 2011), generally display-
ing comparable virological and immunological 
efficacy, but with distinct toxicity profiles. Al-
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though data from clinical trials indicate a low 
incidence of serious renal adverse events, pro-
longed TDF use has been associated with renal 
impairment (Cooper et al., 2010), whose revers-
ibility is still unclear, and cohort studies have 
linked TDF use to reduced estimated glomeru-
lar filtration rate (eGFR) (Fux et al., 2007), ac-
celerated eGFR decline (Campbell et al., 2009), 
proximal tubular dysfunction (Horberg et al., 
2010; Labarga et al., 2009), proteinuria (Gup-
ta et al., 2009), chronic kidney disease (CKD) 
(Scherzer et al., 2012; Mocroft et al., 2010) and 
increased mortality (Campbell et al., 2012). On 
the other hand, ABC use has been associated 
with an increased risk of CVD, mainly myocar-
dial infarction (Friis-Møller et al., 2010; Hsue et 
al., 2009). The issue is still discussed because 
recent studies showed no differences in the on-
set of CV events between ABC/3TC and TDF/
FTC, and several meta-analyses of randomized 
clinical trials have not confirmed previous as-
sociations between ABC use and increased CV 
risk (Wohl et al., 2014; Martin et al., 2010; Ding 
et al., 2012; Cruciani et al., 2011).
From a pathogenetic perspective, several stud-
ies have focused on the biological mechanisms 
and on the biomarkers potentially involved in 
the cardiovascular dysfunction of patients re-
ceiving ABC. The first randomized controlled 
trial demonstrating a relationship between 
ABC and CVD biomarkers was the SMART 
study (INSIGHT/DAD Study Groups, 2008), 
where higher values of IL-6 and high-sensitivity 
CRP were reported with ABC compared to oth-
er NRTIs. Another study (BICOMBO) reported 
no differences between ABC/3TC and TDF/FTC 
in any of the biomarkers investigated (Martínez 
et al., 2010). Different potential mechanisms, 
including endothelial dysfunction, have been 
investigated, but no clear biological cause has 
been recognized, and recent results seem to in-
dicate that endothelial dysfunction, enhanced 
inflammation, and altered coagulation markers 
are unlikely to be mechanisms by which the 
drug could increase this risk (Hsue et al., 2009; 
Wohl et al., 2014). Moreover, although available 
data are not always consistent, HIV-1 infection 
per se has been associated, both in naïve and in 
cART-treated subjects, with increased levels of 
inflammation and coagulation markers (Deeks, 
2009). HIV-1 induced activation of inflamma-
tory and coagulation pathways, with elevated 
levels of interleukin-6 (IL-6), high-sensitivity 
C-reactive protein (hsCRP), and D-dimer might 
therefore increase the risk of cardiovascular 
diseases and mortality, as suggested by recent 
studies (Nordell et al., 2014).
A global evaluation of current regimens that in-
clude metabolic, inflammation and coagulation 
markers may therefore provide relevant infor-
mation for therapeutic decisions. Current treat-
ment guidelines suggest optimizing cART in 
virologically suppressed patients with simplifi-
cation strategies that reduce the pill burden and 
increase adherence and with switching strategies 
that prevent/reduce long-term drug toxicities 
and inflammation, without compromising sta-
ble viral suppression (DHHS HIV/AIDS Guide-
lines, 2014; Italian HIV/AIDS Guidelines, 2014). 
Within this scenario, the aim of our study was 
to perform a comprehensive evaluation of safety 
and efficacy markers in patients switching to the 
ABC/3TC fixed-dose combination from different 
NRTI backbones, represented by ZDV-based reg-
imens (strategy: simplification) and TDF-based 
backbone (strategy: prevention or minimization 
of long-term drug-related toxicities). 
METHODS
Patients
This study was an open-label, observational, 
non-randomized, prospective trial to compare 
the safety and efficacy of switching from ZDV or 
TDF containing regimens to a fixed-dose back-
bone of ABC/3TC 600/300 mg daily. Inclusion 
criteria were: documented HIV-1 infection with 
undetectable HIV-1 RNA load (<37 copies/mL) 
with current regimen from at least 24 months, 
and ZDV/3TC (arm 1), or TDF/FTC (arm 2) as 
ongoing NRTI backbones from more than 24 
months. Exclusion criteria were prior use of 
ABC, diabetes mellitus, untreated hypertension, 
pregnancy, alcohol abuse, or positivity for the 
HLA-B5701 allele upon screening. Demograph-
ic and clinical information (smoking habit, 
CD4+ T cell nadir, HIV-1 RNA load, duration of 
HIV-1 infection and previous cART exposure) 
was retrieved from the patients’ records.
According to current Italian guidelines, a treat-
ment optimization strategy was applied in both 
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arms in order to improve adherence (mainly 
in the ZDV/3TC recipients) and to prevent or 
minimize long-term toxicities (i.e., referred/
observed lipodystrophy, dyslipidemia, re-
nal and bone impairment) (Italian HIV/AIDS 
Guidelines, 2014). All patients maintained the 
same anchor drug they were taking before the 
enrollment in the study. The study took place 
at the Department of Clinical Medicine, “Sa-
pienza” - University of Rome, Italy. Patients 
were followed up clinically until 48 weeks from 
the enrollment. The study was approved by 
the local Ethics Committee (approval number 
2687-216/13). Written informed consent was 
obtained from each patient before enrollment. 
The investigation was conducted in adherence 
to the declaration of Helsinki’s guidelines.
Efficacy and safety parameters
Main endpoints of the study were efficacy and 
safety profiles after 48 weeks from the switch. 
Efficacy profile was evaluated monitoring HIV-
1 RNA levels and CD4+ T cell counts and per-
centages at enrollment and after 48 weeks. Vi-
rologic failures were defined as the inability to 
maintain suppression of viral replication to an 
HIV RNA level <37 copies/mL in two consec-
utive determinations taken one month apart, 
whereas virologic blips were isolated detectable 
HIV RNA values (>37 copies</mL) that are fol-
lowed by a return to virologic suppression.
Safety was investigated through the analysis of 
serum levels of fasting total cholesterol (TC), 
high density lipoprotein cholesterol (cHDL), 
low density lipoprotein cholesterol (cLDL), 
fasting glucose and triglycerides. Renal func-
tion was monitored through serum creatinine 
levels, serum phosphate, and eGFR using the 
Cockcroft-Gault formula and the MDRD (Mod-
ification of Diet in Renal Disease) Study equa-
tion formula.
Bone metabolism was investigated in a subset 
of patients of both arms evaluating bone mass 
density (BMD) in hip and lumbar spine by dual 
energy x ray absorptiometry (DEXA) scans at 
switch time. Serum levels of 25-OH vitamin D 
were measured by electrochemiluminescence 
(ECLIA) with the Elecsys Vitamin D3 (25-OH) 
reactive (Roche Diagnostic GmbH, Mannheim, 
Germany) using the Roche/Hitachi COBAS E 
601 clinical chemistry analyzer. BMI was calcu-
lated as the weight in kilograms divided by the 
square of the height in meters.
Biomarker measurements 
Study biomarkers were evaluated in batch on 
plasma samples stored and maintained at -80°C 
until analysis. To identify changes in inflamma-
tion and metabolic/coagulation markers and 
cytokines, we analyzed plasma levels of tumor 
necrosis factor-α (TNF-α), IL-6, fibrinogen, 
D-dimer, adiponectin, and resistin at baseline 
and at week 48 from enrollment in the study. 
Commercial available enzyme-linked immuno-
sorbent assays (ELISA) were used for plasma 
quantification of IL-6 (R&D Systems, Minne-
apolis, MN, USA), TNF-alpha (R&D Systems, 
Minneapolis, MN, USA), resistin (Enzo Life 
Sciences Inc., NY, USA), and adiponectin (Ad-
ipogen International, San Diego, CA, USA). All 
analyses were performed following the manu-
facturer’s instructions. All measurements were 
performed in duplicate. Samples with unde-
tectable levels were assigned the value of the 
lower detection limit.
Statistics
Results were summarized as proportions and 
as means with standard deviation (SD) or as 
medians with interquartile range (IQR), ac-
cording to the characteristics of data distribu-
tion (normal or skewed, respectively). Groups 
were compared using the c2 test or the Fisher 
test for categorical variables and the T-test or 
the Mann-Whitney U test for quantitative vari-
ables. Multivariable linear regression analyses 
were used to evaluate the impact of multiple 
covariates on dependent quantitative variables 
(e.g. mean changes from baseline in cholesterol 
levels or CD4+ T cell counts). P values below 
0.05 were considered statistically significant. 
All statistical analyses were conducted using 
the SPSS software, version 22.0 (IBM, Somers, 
NY, USA).
rESuLTS
Study participants
Between January and October 2012, forty HIV-
1 infected patients, 17 on a ZDV/3TC backbone 
(arm 1) and 23 on a TDF/FTC backbone (arm 
A. Fantauzzi, M. Floridia, F. Falasca, P. Spanedda, O. Turriziani, V. Vullo, I. Mezzaroma534
2), were included in the study. Two patients in 
arm 1 who withdrew shortly after enrollment 
(because of onset of diabetes mellitus, and alco-
hol abuse with adherence issues, respectively), 
and never received the ABC/3TC regimen, were 
excluded from all analyses. All the remaining 
subjects (n=38) completed the study follow up 
and were included in all analyses. None of the 
study participants had been receiving system-
ic corticosteroids, bisphosphonates, vitamin 
D, calcium or other therapies known to affect 
bone metabolism at enrolment. 
Baseline general characteristics were similar 
in the two arms, with a low number of females 
enrolled, a low percentage of active smokers 
and low rate of hepatitis C virus (HCV) co-in-
fection (Table 1). Route of transmission, stage 
of disease and HIV-related parameters (includ-
ing current and nadir CD4+ T cell levels) were 
also similar in the two groups, with a trend for 
a more frequent use of NNRTIs in arm 2, due to 
the prescription of efavirenz-based co-formu-
lated triple combination regimens. 
Baseline metabolic evaluation (Table 2) showed 
no significant differences between the two arms 
in fasting glucose, triglycerides, cholesterol (in-
cluding HDLc and LDLc), serum phosphate or 
creatinine levels. Patients in arm 2 (TDF/FTC) 
had however significantly lower values of esti-
mated glomerular filtration rate with both the 
MDRD and the Cockcroft-Gault equations. Lev-
els of vitamin D, measured in a subset of patients, 
were slightly higher in arm 1, although not sig-
nificantly. However, these levels were below the 
normal ranges in the majority of evaluated pa-
tients, without increased values of parathyroid 
hormone. The markers of inflammation and co-
agulation (ESR, CRP, fibrinogen and D-dimer) 
were substantially identical in the two groups, 
and the overall baseline cytokine profile was also 
similar, except for higher values of resistin in pa-
tients on the TDF/FTC backbone (Table 2).
Efficacy and safety evaluations
Mean changes from switch in CD4+ T cell 
counts, lipid profiles, and renal parameters 
TABLE 1 - Demographics and main clinical characteristics. Values are reported as mean ± SD  
or proportion (%).
ALL (n=38) ZDV/3TC (n=15) TDF/FTC (n=23) P value
Male sex, n (%) 26 (68.4) 12 (80) 14 (60.9) 0.294
Mean age (years) 45.0±8.4 43.7±9.2 45.9±8.0 0.443
Active smokers, n (%) 12 (31.6) 4 (26.7) 8 (34.8) 0.599
BMI (kg/m2) 22.9±3.1 23.5±2.7 22.4±3.3 0.289
HCV-coinfected, n (%) 7 (18.4) 2 (13.3) 5 (21.7) 0.681
HIV-1 transmission, n (%)
   Heterosexual contacts
   MSM
   Drug injection
18 (47.4)
12 (31.6)
8 (21.1)
7 (46.7)
5 (33.3)
3 (20)
11 (47.8)
7 (30.4)
5 (21.7)
0.456
0.980
0.896
Time since HIV-1 diagnosis (years) 16.2±6.2 15.2±6.9 16.9±5.8 0.427
Time of cART exposure (years) 13.6±5.9 14.6±6.8 12.9±5.3 0.397
NNRTIs exposure at baseline, n (%) 24 (63.2) 7 (46.7) 17 (73.9) 0.089
PIs exposure at baseline, n (%) 11 (28.9) 7 (46.7) 4 (17.4) 0.073
INIs exposure at baseline, n (%) 3 (7.9) 1 (6.7) 2 (8.7)
HIV-1 disease stage, n (%)
   CDC-A
   CDC-B
   CDC-C
22 (57.9)
12 (31.6) 
4 (10.5)
10 (66.7)
4 (26.7)
1 (6.6)
12 (52.2)
8 (34.8)
3 (13)
CD4+ T cell nadir (cells/ml) 263±102 274±101 256±105 0.605
CD4+ T cells, % 34.7±10.1 33.0±10.6 35.9±9.8 0.392
CD4+ T cells (cells/ml) 781±324 786±343 778±319 0.942
SD: standard deviation; ZDV: zidovudine; 3TC: lamivudine; TDF: tenofovir difumarate; FTC: emtricitabine; BMI: body mass index; HCV: he-
patitis C virus; cART: combined antiretroviral treatment; MSM: men who have sex with men; NNRTIs: non-nucleoside reverse transcriptase 
inhibitors; PIs: protease inhibitors; INIs: integrase inhibitors; CDC: Centers for Disease Control and Prevention.
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are shown in Table 3. CD4+ T cells rose in both 
groups, with a trend for a larger increase in 
patients switching from TDF/FTC. Patients in 
both arms remained virologically suppressed 
(HIV-1 RNA levels <37 copies/mL) after the 
switch to ABC/3TC throughout the study, with 
no virological failures or blips during the 48 
weeks of follow up. No serious adverse events 
occurred throughout the observation time, and 
no grade 3 or 4 adverse events were reported 
during the 48 week follow-up.
Fasting glucose remained substantially un-
changed, whilst lipid profile showed different 
trends, with a significant difference between the 
two groups for mean change from baseline in 
total cholesterol (+28.8 mg/dl in patients switch-
ing from ZDV/3TC vs. -1.0 mg/dl in patients 
switching from TDF/FTC; p=0.016). A similar 
but not significant trend was observed for tri-
glycerides and LDLc, that tended to increase in 
patients switching from ZDV/3TC, remaining 
substantially unchanged in patients switching 
from TDF/FTC. HDLc levels showed a mild in-
crease in both groups. Renal parameters also 
showed a mild worsening in patients switching 
from ZDV/3TC compared to no change in pa-
tients switching from TDF/FTC. The significant 
difference between the two groups in total cho-
lesterol during follow up was further explored 
in multivariable analyses in order to evaluate 
the role of potential confounders and adjust for 
covariates. Data were analyzed in a multivari-
able linear regression model which used the 
difference in total cholesterol values between 
0 and 48 weeks as the dependent variable and 
smoking, body mass index, protease inhibitor 
use and treatment group as independent vari-
ables. After adjusting for the above covariates, 
baseline treatment at switch remained the only 
significant predictor of the increase in choles-
terol after switch, with an adjusted estimated 
difference between baseline treatment groups 
of 26.5 mg/dl (95%CI 0.8-52.1) (p=0.044). The 
full results of this multivariable analysis with 
TABLE 2 - Baseline profiles.
ALL (n=38) ZDV/3TC (n=15) TDF/FTC (n=23) P value
A) Lipid and renal markers. Values are reported as mean ± SD.
Fasting glucose (mg/dl) 84.9±8.6 85.0±8.4 84.9±8.9 0.964
Total fasting cholesterol (mg/dl) 199.6±44.5 197.5±35.8 201.0±50.1 0.817
Fasting cLDL (mg/dl) 122.6±33.6 127.1±31.5 119.7±35.4 0.517
Fasting cHDL (mg/dl) 50.2±13.3 48.7±13.7 51.2±13.2 0.587
Fasting triglycerides (mg/dl) 168.3±128.2 184.3±147.5 157.9±116.2 0.542
Serum creatinine (mg/dl) 0.87±0.14 0.85±0.13 0.88±0.14 0.439
Estimated creatinine clearance: 
MDRD (mL/min)
Cockcroft-Gault (mL/min)
91.0±16.2
102.3±26.4
99.9±16.1
112.9±25.2
85.2±13.8
95.5±25.3
0.005
0.045
25-OH D2/D3 vitamin D (ng/ml) 21.7±6.8 25.2±5.4 19.7±7.1 0.214
Serum phosphate (mg/dL) 3.1±0.6 3.1±0.7 3.0±0.6 0.735
B) Inflammation and coagulation markers. Values are reported as mean ± SD.
ESR (mm/h) 11.7±7.5 12.3±8.0 11.3±7.4 0.694
CRP (mg/dL) 2101±3283 1788±3098 2373±3521 0.647
Fibrinogen (g/L) 2.63±0.76 2.69±0.86 2.58±0.69 0.688
D-dimer (ng/ml) 270.1±184.2 225.2±74.4 311.8±242.5 0.212
C) Serum cytokines. Values are reported as median (IQR).
IL-6 (pg/mL): Median values (IQR) 7.8 (7.8-11.7) 7.8 (7.8-11.7) 7.8 (7.8-16.2) 0.697
TNF-α (mg/mL) Median values (IQR) 15.6 (15.6-15.6) 15.6 (15.6-15.6) 15.6 (15.6-18.9) 0.525
Adiponectin (mg/mL) Median values (IQR) 10.1 (5.95-19.4) 10.1 (5.9-16.8) 10.2 (6.1-24.5) 0.637
Resistin (ng/mL) Median values (IQR) 7.3 (4.0-10.5) 4.9 (2.6-7.9) 10.0 (5.5-27.5) 0.031
SD: standard deviation; ZDV: zidovudine; 3TC: lamivudine; TDF: tenofovir difumarate; FTC: emtricitabine; cLDL: low density lipoprotein cho-
lesterol; cHDL: high density lipoprotein cholesterol; MDRD: Modification of Diet in Renal Disease Study equation formula; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; IQR: interquartile range; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α.
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the estimate effect for all variables are shown 
in Table 4.
Similar multivariable linear regression analy-
ses were performed using CD4+ T cell change 
from baseline as dependent variable and dura-
tion of cART treatment, CD4+ T cell nadir, HCV 
coinfection, treatment with protease inhibitors, 
history of toxicity and baseline treatment group 
as covariates, with no significant associations 
found.
Vitamin D measurements were available at 
baseline for 11 patients (4 ZDV/3TC, 7 TDF/
FTC). Mean value was 21.7 ng/ml (SD 6.8). No 
statistically significant differences between 
treatment groups were present (25.2 vs. 19.7 
ng/ml, respectively, p=0.214). Due to the gener-
alized low vitamin D levels, according to HIV-1 
treatment guidelines patients received a per os 
colecalciferol replacement.
Baseline data on bone mineral density were 
available for 22 subjects. Overall, a reduced 
bone mineral density was observed in nine 
subjects of the entire group (40.9%), 3/6 (50%) 
of subjects switching from ZDV/3TC and 6/16 
subjects (37.5%) switching from TDF/FTC 
(p=0.655). 
Inflammation/coagulation biomarkers and cyto-
kines
No significant differences were observed in the 
values of erythrocyte sedimentation rate, CRP, 
fibrinogen, and d-dimer between study groups 
at baseline (Table 2) or at 48 weeks follow-up 
(data not shown). 
TABLE 3 - Changes between baseline (switch time point) and week 48 in the main laboratory parameters.
A) Metabolic markers (mean change ± SD)
ALL ZDV/3TC TDF/FTC P value
Fasting glucose (mg/dl) -0.26±7.5 -1.4±6.6 -0.47±8.1 0.459
Fasting total cholesterol (mg/dl) 10.8±38.1 28.8±42.4 -1.0±30.5 0.016
Fasting LDLc (mg/dl) 5.1±26.8 11.7±26.8 0.83±26.5 0.228
Fasting HDLc (mg/dl) 5.2±14.5 6.3±16.0 4.4±13.8 0.700
Fasting triglycerides (mg/dl) 6.9±124.9 29.6±139.5 -7.9±115.1 0.373
Serum creatinine (mg/dl) 0.01±0.08 0.05±0.10 -0.01±0.06 0.031
MDRD (mL/min) -1.42±10.6 -5.16±13.8 1.01±7.2 0.127
Cd4+ T (cells/ml) 52.9±153.6 16.6±151.9 76.6±153.4 0.245
CD4+ T (%) -0.10±5.4 1.38±3.9 -1.06±6.09 0.177
B) Median changes in serum adiponectin and resistin levels (IQR).
ALL ZDV/3TC TDF/FTC P value
Serum adiponectin (mg/mL) 3.2 (-3.6-8.0) 6.4 (2.2-18.2) 2.0 (-8.6-3.9) 0.030
Serum resistin (ng/mL) 1.4 (-4.8-6.0) 2.7 (-1.3-8.0) 1.4 (-1.0-5.3) 0.313
SD: standard deviation; LDLc: low density lipoprotein cholesterol; HDLc: high density lipoprotein cholesterol; MDRD: Modification of Diet 
in Renal Disease Study equation formula; IQR: interquartile range). P values are determined by using Student T test (Section A) and Mann-
Whitney U test (Section B).
TABLE 4 - Multivariable regression analysis of variables independently associated with cholesterol change  
(mg/dl) between baseline and week 48. 
Variable Coefficient (B) B 95% Confidence limits P value
lower upper
Body Mass Index (per unitary increase) -2.266 -6.193 1.662 0.249
Status of current smoker -4.654 -29.539 20.231 0.706
Ritonavir-boosted protease inhibitors in the regimen 18.629 -9.088 46.347 0.181
ZDV/3TC group 26.493 0.795 52.190 0.044
Coefficient (B) indicates the estimated adjusted difference in change (in mg/dl) between baseline and week 48 in total cholesterol levels (de-
pendent variable) between subjects with/without the relevant characteristic for dichotomic independent variables (status of current smoker, 
ritonavir-boosted protease inhibitors in the regimen, ZDV/3TC group) or the estimated adjusted change attributable to any unitary increase 
in the quantitative independent variable (Body Mass Index).
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Baseline information for cytokine levels was 
available for 30 patients (ZDV/3TC 14, TDF/FTC 
16) and is summarized in Table 2. The majori-
ty of samples showed non-detectable values of 
IL-6 and TNF-α in both arms. Median values of 
adiponectin levels were substantially identical 
in the two groups, while resistin levels were sig-
nificantly higher in patients in TDF/FTC: medi-
an 10.0 ng/ml (IQR 5.5-27.5); ZDV/3TC: median 
4.9 ng/ml (IQR 2.6-7.9), p=0.031 (Table 2).
Information on cytokine levels at 48 weeks was 
available for 23 patients (ZDV/3TC: 10; TDF/
FTC: 13). As for baseline, most of the patients 
showed undetectable levels of IL-6 (60.9%) and 
TNF-α (82.6%), with no differences between 
treatment groups (data not shown). Changes 
from baseline in adiponectin and resistin levels 
are shown in Table 3. For resistin, both median 
changes between baseline and 48 weeks (+2.7 
ng/ml vs. +1.4 ng/ml, p=0.313), and median lev-
els at 48 weeks (6.5 vs. 8.4 ng/ml, p=0.410) were 
similar in the two groups. 
Adiponectin values, conversely, showed a sig-
nificantly higher increase during follow up in 
patients switching from ZDV/3TC compared 
to patients switching from TDF/FTC (median: 
6.4 mg/ml vs. 2.0 mg/ml, p=0.030). Final levels 
were higher in patients who switched from ZD-
V/3TC (median 14.0 vs. 10.4 mg/ml, p=0.021), 
with 4/10 patients in this group (40%) showing 
levels above the upper normal limit of 19 mg/ml 
compared to 1/13 (7.7%) among patients who 
switched from TDF/FTC (p=0.127). No correla-
tions were found between adiponectin levels 
and the metabolic and inflammation/coagu-
lation parameters (i.e., ESR, CRP, fibrinogen, 
d-dimer, IL-6, TNF-a) evaluated in the study.
DISCuSSION
Current HIV/AIDS treatment guidelines rec-
ommend cART optimization in virologically 
suppressed subjects for the following reasons: 
documented toxicity or side effects; preven-
tion of long-term toxicity (pre-emptive switch); 
therapy in place that might aggravate concom-
itant comorbidities; interactions with other 
drugs; need to treat coinfections (i.e., TB, HBV, 
HCV); need to improve adherence; planning of 
pregnancy; patient’s request, and being on an 
antiretroviral regimen which is no longer rec-
ommended. Optimization may be conducted 
reducing the number/dosing of antiretroviral 
drugs or through other switching strategies 
(DHHS HIV/AIDS Guidelines, 2014; Italian 
HIV/AIDS Guidelines, 2014). In this study 
based on common clinical practice, the main 
reasons for optimizing the N(t)RTI backbone to 
ABC/3TC fixed dose combination were differ-
ent: simplification for better adherence in the 
ZDV/3TC group, and presence or prevention of 
long term toxicities, including renal function/
bone metabolism deterioration, in patients tak-
ing TDF/FTC.
In terms of treatment efficacy, all patients re-
mained virologically suppressed during the 
study time, no blips of viremia were detect-
ed, and CD4+ T cell counts increased in both 
groups, with a trend for better response in pa-
tients switching from TDF/FTC. Overall, the 
findings support the strategy as effective in 
both groups. The significant effect of baseline 
treatment group on subsequent CD4+ response 
was confirmed in a multivariable analysis that 
adjusted for duration of cART treatment, CD4+ 
T cell nadir, HCV coinfection, treatment with 
protease inhibitors, and history of toxicity. The 
increase observed in both groups may be due 
to distinct reasons, represented by removal of 
ZDV-induced myelotoxicity and better adher-
ence with QD regimens in patients previously 
receiving ZDV/3TC and by T-cell redistribution 
or effects on precursor cells for patients previ-
ously taking TDF/FTC, as suggested by other 
comparative trials of the two backbones (Eron 
et al., 2006; Sax et al., 2011).
In terms of lipid profile, this remained sub-
stantially unchanged in patients switching 
from TDF/FTC to ABC/3TC, while patients who 
switched from ZDV/3TC to ABC/3TC experi-
enced a significant increase in total cholesterol, 
accompanied by non-significant increases in all 
the other lipid parameters evaluated. The sig-
nificant role of baseline treatment group in de-
termining cholesterol changes after switch was 
confirmed by a multivariable analysis that ad-
justed for smoking, body mass index and prote-
ase inhibitor use, and requires further evalua-
tions in order to define its clinical significance. 
It is important to note that we were unable to 
control for other cofactors potentially involved, 
A. Fantauzzi, M. Floridia, F. Falasca, P. Spanedda, O. Turriziani, V. Vullo, I. Mezzaroma538
such as lifestyle modifications, diet, and possi-
ble introduction of lowering lipid agents (i.e. 
statins) not monitored during the study. Pa-
tients on TDF/FTC had lower eGFR values at 
entry, as expected, given the well-known tox-
icity profile of TDF. However, this group had 
better changes in renal function parameters 
during follow up, thus suggesting that switch-
ing to ABC/3TC may produce positive effects on 
renal function.
With respect to inflammation and coagula-
tion markers, our data showed no significant 
differences between the two groups and no si-
gnificant changes from baseline, suggesting a 
limited impact of switching on the existing in-
dividual patient profile. It has however to be 
considered that the entire population studied 
was characterized by undetectable viral load 
throughout the study, and that therefore HIV-
induced inflammation in this context is likely 
to be substantially reduced. Similar considera-
tions may be valid for the profile of pro-inflam-
matory cytokines: serum levels of both IL-6 e 
TNFα were below the threshold of detection in 
the majority of patients of both groups before 
and after switching, probably reflecting a status 
of low activation of HIV-induced inflammation. 
One of the adipocytokines is resistin, a protein 
hormone that seems to be involved in the pro-
cess of blood glucose regulation, although its bi-
ological function in humans has not been fully 
identified yet (Bienek et al., 2012; Cieslak et al., 
2011). Although resistin values were significan-
tly higher at baseline in patients on TDF/FTC, 
changes from baseline were similar in the two 
groups and the final levels at 48 weeks were also 
similar, suggesting limited impact of switching 
to ABC/3TC on this parameter. The data on ad-
iponectin (an anti-inflammatory hormone also 
correlated with the presence of lipodystrophy), 
that indicate a significantly higher increase for 
switching from ZDV/3TC, although based on a 
limited number of cases, may warrant further 
investigations, particularly to define the me-
chanisms that linked this particular group to 
a common increase in adiponectin levels and 
lipid parameters. Such investigations may also 
be useful to define the potential mechanisms 
responsible for increased cardiovascular risk 
in patients taking ABC. The results should ho-
wever be interpreted cautiously, given the low 
number of cases and the absence of any cor-
relation observed between adiponectin values 
and the main metabolic parameters studied.
This study has some limitations, represented 
by low number of cases, the absence of detai-
led immunological evaluations (e.g. additional 
lymphocyte subsets or cytokines), and lack of 
information on more directly relevant measu-
res of cardiovascular risk, such as intima media 
thickness or flow mediated dilation. The short 
period of follow-up and the limited sample size 
also precluded evaluation of clinical cardio-
vascular events, but most of these evaluations 
were beyond the objectives of this pilot study.
In conclusion, the findings of this study sug-
gest that switching the N(t)RTI backbone to 
ABC/3TC fixed-dose combination was overall 
effective, safe and well tolerated in virologically 
suppressed HIV-1 patients on either ZDV/3TC 
or TDF/FTC. Levels of inflammatory markers 
were low and were not influenced by switching 
to ABC/3TC, in either group. Some changes in 
metabolic, kidney and cytokine profiles were 
apparently specific for baseline treatment 
group, but further evaluations are needed to 
define their clinical significance. Overall, these 
preliminary results should be further investiga-
ted in larger studies.
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